Genprex Raises $8.1 Million in Registered Direct Offering and Private Placement
Genprex Inc. has raised $8.1 million through a registered direct offering and a concurrent private placement. The registered offering includes the sale of 243,622 shares at $11.21 each, totaling approximately $2.7 million. Additionally, the company will issue unregistered short-term warrants for up to 487,244 shares at an exercise price of $11.00, potentially generating an extra $5.4 million if fully exercised. The funds will be used for working capital and general corporate purposes, with H.C. Wainwright & Co. as the exclusive placement agent.
Genprex Inc., a clinical-stage gene therapy company, has announced a registered direct offering of approximately $2.7 million through the sale of 243,622 shares of common stock at $11.21 per share. In a concurrent private placement, the company will issue unregistered short-term warrants to purchase up to 487,244 shares of common stock at an exercise price of $11.00 per share. These warrants will be immediately exercisable and will expire 24 months after the effective date of a registration statement for the underlying shares. If fully exercised, the warrants could yield an additional $5.4 million in gross proceeds. Genprex plans to use the net proceeds for working capital and general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA05439) on October 23, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
